

Teresa P Y Chiang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7468958/publications.pdf>

Version: 2024-02-01

45
papers

1,265
citations

430442

18
h-index

395343

33
g-index

49
all docs

49
docs citations

49
times ranked

2114
citing authors

#	ARTICLE	IF	CITATIONS
1	Coronavirus Disease 2019-associated Pulmonary Aspergillosis in Mechanically Ventilated Patients. <i>Clinical Infectious Diseases</i> , 2022, 74, 83-91.	2.9	76
2	Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 293-295.	0.5	57
3	Offer Acceptance Patterns for Liver Donors Aged 70 and Older. <i>Liver Transplantation</i> , 2022, 28, 571-580.	1.3	4
4	Antibody response to 2-dose SARS-CoV-2 mRNA vaccination in pediatric solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2022, 22, 669-672.	2.6	25
5	Six-month Antibody Kinetics and Durability in SARS-CoV-2 mRNA Vaccinated Solid Organ Transplant Recipients. <i>Transplantation</i> , 2022, 106, e109-e110.	0.5	17
6	Attenuated response to fourth dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 738-740.	0.5	20
7	6-mo Antibody Kinetics and Durability After 3 Doses of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients. <i>Transplantation</i> , 2022, Publish Ahead of Print, .	0.5	6
8	Impact of the COVID-19 pandemic on transplantation by income level and cumulative COVID-19 incidence: a multinational survey study. <i>BMJ Open</i> , 2022, 12, e055367.	0.8	1
9	Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease. <i>Lancet Rheumatology</i> , The, 2022, 4, e241-e243.	2.2	22
10	Prevalence and Durability of SARS-CoV-2 Antibodies Among Unvaccinated US Adults by History of COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1085.	3.8	48
11	Improved Antibody Response After a Fifth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. <i>Transplantation</i> , 2022, 106, e262-e263.	0.5	27
12	Effect of Mycophenolate Mofetil Dosing on Antibody Response to SARS-CoV-2 Vaccination in Heart and Lung Transplant Recipients. <i>Transplantation</i> , 2022, 106, e269-e270.	0.5	16
13	Humoral and Cellular Immune Response to a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients Taking Belatacept. <i>Transplantation</i> , 2022, 106, e264-e265.	0.5	8
14	Factors associated with poor antibody response to third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases. <i>Lancet Rheumatology</i> , The, 2022, 4, e382-e384.	2.2	9
15	Severe acute respiratory syndrome coronavirus 2 antibody response to a third dose of homologous messenger RNA vaccination in liver transplantation recipients. <i>Liver Transplantation</i> , 2022, 28, 1393-1396.	1.3	6
16	Quantifying excess deaths among solid organ transplant recipients in the COVID-19 era. <i>American Journal of Transplantation</i> , 2022, 22, 2077-2082.	2.6	26
17	Outcomes of SOT Recipients With COVID-19 in Different Eras of COVID-19 Therapeutics. <i>Transplantation Direct</i> , 2022, 8, e1268.	0.8	14
18	Antibody Response to a Fourth Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: An Update. <i>Transplantation</i> , 2022, 106, e338-e340.	0.5	21

#	ARTICLE	IF	CITATIONS
19	Heterologous Ad.26.COVS versus homologous BNT162b2/mRNA-1273 as a third dose in solid organ transplant recipients seronegative after two-dose mRNA vaccination. American Journal of Transplantation, 2022, 22, 2254-2260.	2.6	16
20	Antibody response to three SARS-CoV-2 mRNA vaccines in adolescent solid organ transplant recipients. American Journal of Transplantation, 2022, 22, 2481-2483.	2.6	4
21	Comparison of SARS-CoV-2 Antibody Response After 2-Dose mRNA-1273 vs BNT162b2 Vaccines in Incrementally Immunosuppressed Patients. JAMA Network Open, 2022, 5, e2211897.	2.8	15
22	Safety of third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal disease. Rheumatology, 2022, 61, e302-e304.	0.9	4
23	Improved humoral immunogenicity with mRNA-1273 versus BNT162b2 as third vaccine dose among solid organ transplant recipients seronegative after two BNT162b2 doses. Clinical Transplantation, 2022, 36, .	0.8	0
24	Safety and immunogenicity of fifth dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series. Rheumatology, 2022, 61, e360-e362.	0.9	2
25	Immunogenicity of Ad26.COVS prime and two subsequent doses of mRNA SARS-CoV-2 vaccines in solid organ transplant recipients: A case series. Clinical Transplantation, 2022, 36, .	0.8	1
26	Letter to the editor: Six-month antibody kinetics and durability in liver transplant recipients after two doses of SARS-CoV-2 mRNA vaccination. Hepatology Communications, 2022, 6, 2990-2992.	2.0	2
27	Inpatient COVID-19 outcomes in solid organ transplant recipients compared to non-solid organ transplant patients: A retrospective cohort. American Journal of Transplantation, 2021, 21, 2498-2508.	2.6	63
28	Effects of COVID-19 pandemic on pediatric kidney transplant in the United States. Pediatric Nephrology, 2021, 36, 143-151.	0.9	20
29	Response to "COVID-19 in SOT versus non-SOT". American Journal of Transplantation, 2021, 21, 2306-2306.	0.6	0
30	Antibody Kinetics and Durability in SARS-CoV-2 mRNA Vaccinated Solid Organ Transplant Recipients. Transplantation, 2021, 105, e137-e138.	0.5	35
31	Kidney Transplant Recipient Attitudes Toward a SARS-CoV-2 Vaccine. Transplantation Direct, 2021, 7, e713.	0.8	11
32	Immunosuppression practices during the COVID-19 pandemic: A multinational survey study of transplant programs. Clinical Transplantation, 2021, 35, e14376.	0.8	13
33	Eplet mismatches associated with de novo donor-specific HLA antibody in pediatric kidney transplant recipients. Pediatric Nephrology, 2021, 36, 3971-3979.	0.9	3
34	Kidney Transplantation Confers Survival Benefit for Candidates With Pulmonary Hypertension. Transplantation Direct, 2021, 7, e738.	0.8	2
35	Antibody Response to the Janssen COVID-19 Vaccine in Solid Organ Transplant Recipients. Transplantation, 2021, 105, e82-e83.	0.5	54
36	SARS-CoV-2 Messenger RNA Vaccine Immunogenicity in Solid Organ Transplant Recipients With Prior COVID-19. Transplantation, 2021, 105, e270-e271.	0.5	19

#	ARTICLE	IF	CITATIONS
37	Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1365-1366.	0.5	22
38	Immunogenicity and Reactogenicity After SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Taking Belatacept. <i>Transplantation</i> , 2021, 105, 2119-2123.	0.5	55
39	Antibody Response to a Fourth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. <i>Transplantation</i> , 2021, 105, e280-e281.	0.5	103
40	Impact of COVID-19 on Lung Allograft and Clinical Outcomes in Lung Transplant Recipients: A Case-control Study. <i>Transplantation</i> , 2021, 105, 2072-2079.	0.5	24
41	Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination. <i>Lancet Rheumatology</i> , The, 2021, 3, e753-e754.	2.2	11
42	Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data. <i>Lancet HIV</i> , the, 2021, 8, e690-e700.	2.1	106
43	Antibody Response to an mRNA SARS-CoV-2 Vaccine Following Initial Vaccination With Ad.26.COV2.S in Solid Organ Transplant Recipients. <i>Transplantation</i> , 2021, Publish Ahead of Print, .	0.5	4
44	Evolving Impact of COVID-19 on Transplant Center Practices and Policies in the United States. <i>Clinical Transplantation</i> , 2020, 34, e14086.	0.8	24
45	Early impact of COVID-19 on transplant center practices and policies in the United States. <i>American Journal of Transplantation</i> , 2020, 20, 1809-1818.	2.6	214